HeartLung Technologies to Present Four Cutting-Edge Research Studies on AI-CAC™, AutoBMD™, and AI-CVD™ at RSNA 2024

December 01, 2024 05:47 AM AEDT | By EIN Presswire
 HeartLung Technologies to Present Four Cutting-Edge Research Studies on AI-CAC™, AutoBMD™, and AI-CVD™ at RSNA 2024
Image source: EIN Presswire
HOUSTON, TX, UNITED STATES, November 30, 2024 /EINPresswire.com/ -- HeartLung Technologies (www.heartlung.ai), a leading developer of innovative AI solutions for early detection of heart disease, lung cancer, and other fatal conditions is pleased to announce that four of its scientific research studies on AI-CAC™, AutoBMD™, and AI-CVD™ have been accepted for presentation at the 2014 Radiological Society of North America (RSNA). The event, which is the largest gathering of doctors and other experts in the field of medical imaging, will be held December 1-4, 2024 in Chicago.

This exciting milestone is achieved shortly after HeartLung Technologies’ seven research presentations at the 2024 Annual Scientific Sessions of the American Heart Association (AHA 2024) held November 16-18, and five research presentations at the 2024 Congress of European Society of Cardiology (ESC 2024) .

“I’m pleased that our years of R&D at HeartLung is finally coming to fruition in patient care” said Dr. Morteza Naghavi, the founder and president of HeartLung Technologies who is also the lead author of the research studies presented at the RSNA 2024. “We’re building the foundation for the future of AI-enabled early detection, monitoring, and prevention of fatal diseases such as heart disease, lung cancer, COPD, osteoporosis, steatosis and other deadly conditions that can be averted”.

HeartLung’s cutting-edge research and innovations have the potential to significantly improve public health by preventing late-stage diseases that are often deadly and costly.

The following studies have been accepted for presentations:

HeartLung Presentation #1:
Session#: M2-SPCA
Session Title: Cardiac Imaging Monday Morning Poster Discussions
Presentation#: M2-SPCA-10
Abstract Title: AI-ENABLED CARDIAC CHAMBERS VOLUMETRY IN CORONARY ARTERY CALCIUM (CAC) SCANS (AI-CAC) SIGNIFICANTLY IMPROVES ON AGATSTON CAC SCORE FOR PREDICTING ALL CARDIOVASCULAR EVENTS: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS
Discussion Date/Time: 12/2/2024 9:00:00 AM-12/2/2024 9:30:00 AM

HeartLung Presentation #2:
Session#: M5A-SPCA
Session Title: Cardiac Imaging Monday Afternoon Poster Discussions I
Presentation#: M5A-SPCA-3
Abstract Title: AI-ENABLED AUTOMATED BONE MINERAL DENSITY MEASUREMENT IN CORONARY ARTERY CALCIUM SCANS (AUTOBMD) IS ASSOCIATED WITH HIGH CORONARY ARTERY CALCIUM SCORE INDEPENDENTLY OF CONVENTIONAL RISK FACTORS: MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
Discussion Date/Time: 12/2/2024 12:15:00 PM-12/2/2024 12:45:00 PM

HeartLung Presentation #3:
Session#: M5A-SPCA
Session Title: Cardiac Imaging Monday Afternoon Poster Discussions I
Presentation#: M5A-SPCA-1
Abstract Title: AUTOMATED LEFT VENTRICULAR VOLUMETRY USING ARTIFICIAL INTELLIGENCE IN CORONARY CALCIUM SCANS (AI-CAC) PREDICTS HEART FAILURE COMPARABLY TO CARDIAC MRI AND OUTPERFORMS NT-PROBNP: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
Discussion Date/Time: 12/2/2024 12:15:00 PM-12/2/2024 12:45:00 PM

HeartLung Presentation #3:
Session#: M5A-SPCA
Session Title: Cardiac Imaging Monday Afternoon Poster Discussions I
Presentation#: M5A-SPCA-2
Abstract Title: CORONARY ARTERY CALCIUM SCANS POWERED BY ARTIFICIAL INTELLIGENCE (AI-CAC) PREDICTS ATRIAL FIBRILLATION AND STROKE COMPARABLY TO CARDIAC MAGNETIC RESONANCE IMAGING: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
Discussion Date/Time: 12/2/2024 12:15:00 PM-12/2/2024 12:45:00 PM

Every year RSNA’s scientific review committee selects presentations through a rigorous peer-review process. The fact that HeartLung Technologies received acceptance for 4 research presentations speaks volume for the scientific power of HeartLung’s outstanding team.

List of RSNA 2024 HeartLung Research Coauthors:
Morteza Naghavi, MDa, Anthony P. Reeves, PhDb, Kyle Atlas, BSa, Chenyu Zhang, MSa, Thomas Atlas, MDc, Claudia Henschke, PhD., MDd, David Yankelevitz, MDd, Matthew J. Budoff, MDe, Dong Li, PhDe, Wenjun Fan, MD, PhDm, Ruilin Yu, MPHn, Andrea Branch, MDd, Ning Ma, PhDd, Rowena Yip, PhDd, Sion K. Roy, MDe, Khurram Nasir, M.Df, Sabee Molloi, PhDg, Zahi Fayad, PhDf, Michael V. McConnell, MD, MSEEh, Ioannis Kakadiaris, MDi, Javier Zuelueta, MDd, David J. Maron, MDh, Jagat Narula, MD, PhDi, Prediman Shah, MDo, Kim Williams, MDj, Daniel Levy, M.Dk, Nathan D. Wong, PhDl.

a. HeartLung.AI, Houston, TX, 77021
b. Department of Electrical and Computer Engineering, Cornell University, Ithaca, NY 14853
c. Tustin Teleradiology, Tustin, CA 92780
d. Mount Sinai Hospital, New York, NY 10029
e. The Lundquist Institute, Torrance, CA 90502
f. Houston Methodist Hospital, Houston, TX 77030
g. Department of Radiology, University of California Irvine, CA 92697
h. Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305
i. The University of Texas Health Science Center at Houston, TX, 77030
j. University of Louisville, Louisville, KY
k. Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, 20824
l. Heart Disease Prevention Program, Division of Cardiology, University of California Irvine, CA 92697
m. Department of Epidemiology & Biostatistics, University of California Irvine, CA 92697
n. Department of Epidemiology, University of California, Los Angeles, CA 90095
o. Cedars-Sinai Medical Center, Los Angeles, CA, 90048

About HeartLung Technologies
HeartLung Technologies aims to help people live long by eliminating preventable deaths caused by heart attacks, lung cancer, osteoporosis, chronic pulmonary obstructive disease (COPD), fatty liver disease, and other deadly medical conditions. HeartLung’s team of industry-leading physicians and engineers are dedicated to increasing people's life-span and health-span by starting with taking out America’s most deadly killers: heart disease and lung cancer. HeartLung is innovating for the millions of Americans and many more worldwide who can benefit from early detection of preventable fatal diseases. HeartLung.AI is a portfolio company of American Heart Technologies (AHT) founded by Dr. Morteza Naghavi, a leader in preventive cardiology and health-tech, former faculty of Texas Heart Institute and University of Texas in 2007. AHT was established as a vehicle for commercialization of innovative healthcare solutions, three of which received FDA approval and were commercialized under portfolio companies Endothelix Inc., and CardioNexus Corp, and HeartLung Corp.

For more information about HeartLung Technologies, please visit www.heartlung.ai. and www.americanhearttechnologies.com

Marlon Montes
HeartLung Corporation
+1 310-510-6004
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube
Other

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.